Middle East and Asia Pacific Cell and Gene Therapy Market, by Therapy Type (Cell Therapy (Stem Cells, T Cells, Dendritic Cells, and NK Cells) and Gene Therapy (Germline Gene Therapy and Somatic Gene Therapy)), by Indication (Dermatology, Musculoskeletal,

Middle East and Asia Pacific Cell and Gene Therapy Market, by Therapy Type (Cell Therapy (Stem Cells, T Cells, Dendritic Cells, and NK Cells) and Gene Therapy (Germline Gene Therapy and Somatic Gene Therapy)), by Indication (Dermatology, Musculoskeletal, Oncology, Immunology, Cardiology & Neurology, and Others), by Technology (Lentiviral Vector, Plasmid DNA, and AAV), and by Region (Middle East and Asia Pacific) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Cell therapy is the administration of living cells in patients for the treatment of a disease such as oncology, Immunology and others. The source of a cell can be autologous or allogeneic, which can be derived from stem cells such as bone marrow. Stem cells therapy is used in bone marrow transplantation. Gene therapy is the introduction, removal, or change in the patient's genetic code for the treatment of a disease. Moreover, it modifies the expression of an individual’s genes or repairs abnormal genes. The therapy involves the administration of nucleic acid (DNA/RNA) with carriers called vectors.
Market Dynamics
Key players are focusing on product approvals and launches to strengthen their position in the Middle East and Asia Pacific cell and gene therapy market. For instance, in March 2021, Novartis received Singapore Health Sciences Authority (HSA) approval for Kymriah (tisagenlecleucel), as the first commercial chimeric antigen receptor T-cell (CAR-T) therapy in Singapore under the new cell, tissue, and gene therapy products (CTGTP) regulatory framework.
Furthermore, in February 2021, the commercial manufacturing of Novartis’s Kymriah was approved by Therapeutic Goods Administration (TGA) in Australia.
Key features of the study:
This report provides an in-depth analysis of the Middle East and Asia Pacific cell and gene therapy market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Middle East and Asia Pacific cell and gene therapy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis International AG, Pfizer, Inc., Sanofi S.A., Amgen, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Bluebird Bio, Inc. (Celgene Corporation), Gene biotherapeutics, Sibiono GeneTech Co. Ltd., Kolon TissueGene, Inc., Horama S.A., MeiraGTx Limited, Gilead Sciences, Inc., Biogen INC., Organogenesis, Inc., JCR Pharmaceuticals Co. Ltd, uniQure N.V., WuxiAppTec, Lonza, and Immuneel Therapeutics Pvt Ltd
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Middle East and Asia Pacific cell and gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Middle East and Asia Pacific cell and gene therapy market
Detailed Segmentation:
Middle East and Asia Pacific Cell and Gene Therapy Market, By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Gene Therapy
Germline Gene Therapy
Somatic Gene Therapy
Middle East and Asia Pacific Cell and Gene Therapy Market, By Indication:
Dermatology
Musculoskeletal
Oncology
Immunology
Cardiology & Neurology
Others
Middle East and Asia Pacific Cell and Gene Therapy Market, By Technology:
Lentiviral Vector
Plasmid DNA
AAV
Middle East and Asia Pacific Cell and Gene Therapy Market, By Region:
Middle East
By Therapy Type
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Gene Therapy
Germline Gene Therapy
Somatic Gene Therapy
By Indication
Dermatology
Musculoskeletal
Oncology
Immunology
Cardiology & Neurology
Others
By Technology
Lentiviral Vector
Plasmid DNA
AAV
By Country
Kingdom of Saudi Arabia
UAE
Israel
Iran
Jordan
Rest of Middle East
Asia Pacific
By Therapy Type
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Gene Therapy
Germline Gene Therapy
Somatic Gene Therapy
By Indication
Dermatology
Musculoskeletal
Oncology
Immunology
Cardiology & Neurology
Others
By Technology
Lentiviral Vector
Plasmid DNA
AAV
By Country
South East Asia
Philippines
Malaysia
Singapore
Thailand
Vietnam
Rest of South East Asia
Taiwan
Hong Kong
Macau
Japan
South Korea
India
Australia
China
Rest Of Asia pacific
Company Profiles
Novartis International AG*
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Pfizer, Inc.
Sanofi S.A.
Amgen, Inc.
Regeneron Pharmaceuticals, Inc.
F. Hoffmann-La Roche AG
Bluebird Bio, Inc. (Celgene Corporation)
Gene biotherapeutics
Sibiono GeneTech Co. Ltd.
Kolon TissueGene, Inc.
Horama S.A.
MeiraGTx Limited
Gilead Sciences, Inc.
Biogen INC.
Organogenesis, Inc.
JCR Pharmaceuticals Co. Ltd
uniQure N.V.
WuxiAppTec
Lonza
Immuneel Therapeutics Pvt Ltd
“*” marked represents similar segmentation in other categories in the respective section.